Home

Innate Pharma S.A. - American Depositary Shares (IPHA)

1.9200
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 4th, 8:29 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.920
Open-
Bid1.890
Ask2.010
Day's RangeN/A - N/A
52 Week Range1.290 - 3.511
Volume178
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume22,579

Chart

About Innate Pharma S.A. - American Depositary Shares (IPHA)

Innate Pharma S.A. is a biotechnology company focused on developing immunotherapy treatments for cancer. The company specializes in harnessing the body’s immune system to target and eliminate cancer cells. Innate Pharma is primarily engaged in the research and development of novel therapeutic antibodies and proprietary platforms that aim to enhance the immune response against tumors. Through its innovative programs, the company collaborates with other organizations to advance its promising candidates through clinical trials, with the ultimate goal of improving outcomes for cancer patients. Read More

News & Press Releases

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News:
By Innate Pharma SA · Via Business Wire · April 3, 2025
Earnings Scheduled For March 27, 2025benzinga.com
Via Benzinga · March 27, 2025
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 27, 2025
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 26, 2025
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 25, 2025
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 20, 2025
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · February 27, 2025
Wondering what's happening in today's pre-market session?chartmill.com
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · February 18, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 18, 2025
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Regulatory News:
By Innate Pharma SA · Via Business Wire · February 17, 2025
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 27, 2025
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 27, 2025
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 21, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 16, 2025
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 10, 2025
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 20, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 16, 2024
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · December 16, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 9, 2024
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 9, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 6, 2024
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 6, 2024
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 3, 2024
Innate Pharma Releases Its 2025 Financial Calendar
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 20, 2024
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 19, 2024